Value of Masks Amid COVID-19: Replay July 10 HD Live!

Follow Our Live Coverage of COVID-19 Developments

Osteoporosis Drug Evista Approved to Cut Risk of Breast Cancer

Among postmenopausal women

Please note: This article was published more than one year ago. The facts and conclusions presented may have since changed and may no longer be accurate. And "More information" links may no longer work. Questions about personal health should always be referred to a physician or other health care professional.

FRIDAY, Sept. 14, 2007 (HealthDay News) -- The Eli Lilly drug Evista (raloxifene) has been approved by the U.S. Food and Drug Administration to reduce the risk of invasive breast cancer among postmenopausal women at high risk for the disease and among postmenopausal women with osteoporosis.

The agency's decision followed recommended approval in July for these new uses by an FDA expert advisory panel, despite concerns that the drug could increase the risks of blood clots and fatal stroke in some women.

Evista was first approved in 1999 to prevent osteoporosis in postmenopausal women.

In a statement, Lilly said the drug's label would now include a boxed warning stressing that women with a history of blood clots known as venous thromboembolisms should not take Evista, and that women at risk for stroke should consult a physician before using the drug.

Women who are pregnant, nursing or who could become pregnant shouldn't take the drug either, Lilly said, and those with kidney or liver problems should speak with their doctor first.

More information

The FDA has more about the approval.

Last Updated: